The Serine/Threonine Protein Kinase Nek7 pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase Nek7 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Serine/Threonine Protein Kinase Nek7 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Central Nervous System, and Gastrointestinal which include the indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome, Systemic Lupus Erythematosus, Inflammation, Alzheimer’s Disease, Neuropathic Pain (Neuralgia), and Unspecified Gastrointestinal Disorders. It also reviews key players involved in Serine/Threonine Protein Kinase Nek7 targeted therapeutics development with respective active and dormant or discontinued products.
The Serine/Threonine Protein Kinase Nek7 pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 3, and 2 respectively.
Serine/Threonine Protein Kinase Nek7 overview
Serine/Threonine Protein Kinase Nek7 (NEK7) is a protein kinase which plays an key role in mitotic cell cycle progression. NEK7 is necessary for microtubule nucleation activity of the centrosome, robust mitotic spindle formation and cytokinesis. It is useful as an essential activator of the NLRP3 inflammasome assembly independently of its kinase activity.
For a complete picture of Serine/Threonine Protein Kinase Nek7’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
